StockNews.com Upgrades Summit Therapeutics (NASDAQ:SMMT) to Hold
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday. Several other research analysts have also commented on SMMT. Summit Redstone set a $35.00 target price on Summit Therapeutics in a research report on Wednesday, March 26th. HC […]
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday. Several other research analysts have also commented on SMMT. Summit Redstone set a $35.00 target price on Summit Therapeutics in a research report on Wednesday, March 26th. HC […]
